Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$1.58 - $1.9 $221 - $266
140 Added 37.33%
515 $861,000
Q1 2024

May 13, 2024

BUY
$1.54 - $2.37 $115 - $177
75 Added 25.0%
375 $698,000
Q4 2023

Feb 09, 2024

BUY
$1.21 - $1.9 $363 - $570
300 New
300 $570,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $78.9M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Frazier Financial Advisors, LLC Portfolio

Follow Frazier Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frazier Financial Advisors, LLC with notifications on news.